Abstracts tagged "dermatomyositis"

Abstract Number: 0339 • ACR Convergence 2024
Clinical Characteristics Associated with Inpatient Mortality in Dermatomyositis Patients: A Single Center Retrospective Cohort Study
Anjana Srikumar, Keon Niknejad, Maria Kaltchenko and Jun Kang, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease associated with higher rates of hospitalization, longer lengths of stay, higher mean hospitalization costs, and increased inpatient…
Abstract Number: 1152 • ACR Convergence 2024
Nailfold Videocapillaroscopy Abnormalities in Different Autoimmune Inflammatory Myopathy Subsets
Thaisa Cotton¹, Valérie Leclair², Claudie Berger³, Yves Troyanov⁴, marie Hudson² and Geneviève Gyger², and Canadian Inflammatory Myopathy Study (CIMS), ¹Université de Montréal, Montreal, QC, Canada, ²McGill University, Montreal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada
Background/Purpose: Nailfold videocapillaroscopy (NVC) alterations have mostly been described in autoimmune inflammatory myopathies (AIM) classified using Bohan and Peter criteria. The aim of this study…
Abstract Number: 1284 • ACR Convergence 2024
Unlocking Insights into Juvenile Dermatomyositis: Clinical and Demographic Profiles Paired with Total Improvement Scores at a Tertiary Center
keerthivardhan yerram¹, phanikumar devarasetti¹ and Liza Rajasekhar², ¹Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, ²Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare autoimmune disorder that predominantly affects the skin and muscles in children under the age of sixteen. Literature on…
Abstract Number: 2081 • ACR Convergence 2024
Proteomic Profiling of Urine Reveals Biomarker Candidates for Idiopathic Inflammatory Myopathies
Xueting Yuan¹, Zhengguang Guo², Jia Shi¹, Shuang Zhou³, Chanyuan Wu⁴, Jiuliang Zhao³, Dong Xu⁵, Mengtao Li⁶, Wei Sun², qian wang⁶ and Xiaofeng Zeng⁷, ¹Peking Union Medical College, Beijing, China, ²Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China, ³Peking union medical college hospital, Beijing, China, ⁴Peking Union Medical College Hospital, Chinese Academy of Medical Sciences& Peking Union Medical College, Beijing, China, ⁵Peking Union Medical College Hospital, Dong Cheng District, Beijing, China, ⁶Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, ⁷Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a rare heterogeneous group of autoimmune diseases characterized by immune-mediated muscle injury. We aimed to examine urine proteomic signatures…
Abstract Number: 0341 • ACR Convergence 2024
Efficacy and Safety of Nintedanib in Patients with Idiopathic Inflammatory Myopathy-related Interstitial Lung Disease
Kaito Aoki¹, Keigo Shimura¹, Toshiki Ohisa¹, Akira Ishii¹, Mai Sugiyama², Yuichiro Ota¹, Ayumi Nishikawa³, Noriko Sasaki³, Chiho Yamada¹ and Shinji Sato², ¹Tokai University School of Medicine, Isehara, Japan, ²Tokai University, Isehara, Japan, ³Tokai University Hachioji Hospital, Hachioji, Japan
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are chronic inflammatory disorders that affect muscle, skin and lung to varying degrees. Interstitial lung disease (ILD) is a major…
Abstract Number: 1154 • ACR Convergence 2024
Comparative Transcriptome Analysis of Murine Model and Human Samples in Anti-Melanoma Differentiation Associated Gene 5 Antibody-positive Rapidly Progressive Interstitial Lung Disease
Yuki Ichimura¹, Risa Konishi², Tadatsune Iida³, Kousuke Negishi⁴ and Naoko Okiyama⁵, ¹Tokyo Women’s Medical University, Tokyo, Japan, ²University of Tsukuba, Tokyo, Japan, ³Institute of Science Tokyo, Tokyo, Japan, ⁴Kawakita General Hospital, Tokyo, Japan, ⁵Institute of Science Tokyo, Toky, Japan
Background/Purpose: Anti-Melanoma differentiation associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) frequently presents with rapidly progressive interstitial lung disease (RP-ILD), leading to a high mortality rate…
Abstract Number: 1424 • ACR Convergence 2024
Associations of Human Leukocyte Antigens (HLA) Class II with Interstitial Lung Disease (ILD) in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs). A Prospective Study in Sequential Patients with SARD-ILD
Panagiotis Panagopoulos¹, Loukas chatzis², Vasiliki Kitsiou³, Katerina Tarassi³, Eirini Chatzinikita⁴, Katerina Malagari⁵, Theodoros Vassilakopoulos⁴, Alexandra Tsirogianni³, Andreas Goules⁶ and Athanasios Tzioufas⁷, ¹Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ²Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ³Immunology and Histocompatibility Department, Evangelismos General Hospital, Athens, Greece, ⁴Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁵2nd Department of Radiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁶GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, ⁷LAIKO HOSPITAL, Athens, Greece
Background/Purpose: Genetic studies in various systemic autoimmune rheumatic diseases (SARDs) support that human leukocyte antigen (HLA) class II alleles are associated with specific autoimmune disorders…
Abstract Number: 2183 • ACR Convergence 2024
Accuracy of AI Tools for Diagnosis of Connective Tissue Disease
Indira Sriram¹, Gabriel Tarshish² and Megan Curran², ¹University of Colorado, Aurora, CO, ²Children's Hospital Colorado, Aurora, CO
Background/Purpose: In this work, we study the ability of generative artificial intelligence (AI) based tools to diagnose pediatric rheumatological diseases. Specifically, we seek to answer…
Abstract Number: 0345 • ACR Convergence 2024
Treatment Patterns and Glucocorticoid Burden of Dermatomyositis Patients: A Cohort Study in the University of Pittsburgh’s Myositis Registry
Chester Oddis¹, Jan Feifel², Dana Ascherman³, Diane Carol Koontz⁴, Caroline Foch², Luisa Henkel⁵, Jeffrey M. Muir⁶, Deborah Denis⁷ and Rohit Aggarwal⁸, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²the healthcare business of Merck KGaA, Darmstadt, Germany, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Merck Healthcare Germany GmbH, an affiliate of Merck KGaA, Darmstadt, Germany, Weiterstadt, Germany, ⁶Cytel, Inc., Toronto, Canada, ⁷EMD Serono, Rockland, MA, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Glucocorticoids (GC) in high doses remain the first-line treatment for dermatomyositis (DM). One or more immunosuppressive agents are given concomitantly as steroid-sparing agents to…
Abstract Number: 1155 • ACR Convergence 2024
Stratification of Cancer Risk in Idiopathic Inflammatory Myopathies. Application of the IMACS Guidelines to Enhance Screening
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³ and elvira Diez álvarez⁴, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, Leon
Background/Purpose: Idiopathic inflammatory myopathies (IIM) carry an elevated risk of cancer incidence. Recently published International Guidelines for IIM-associated cancer screening from the Myositis Assessment and…
Abstract Number: 1537 • ACR Convergence 2024
Discovery of VENT-03: A Novel Clinical cGAS Inhibitor for the Treatment of SLE and Other Autoimmune Diseases
Kelly A. Pike¹, Nadine Fradet¹, Samuel Gaudreault¹, Alexander M Skeldon², Ramsay E. Beveridge², Patrick Cyr², Nicolas Sgarioto², Philippe Le Gros³, Eleftheria Seliniotakis², Valerie Dumais², Jacklyn Smith², James I.P Stewart², Mehrnaz Gharaee-Kermani⁴, Michelle J Kahlenberg⁴ and Michael A. Crackower², ¹Ventus Therapeutics, Saint-Laurent, QC, Canada, ²Ventus Therapeutics, Saint-Laurent, Canada, ³Ventus Therapeutics, Montreal, QC, Canada, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Cyclic GMP-AMP synthase (cGAS) is a nucleic acid sensor that plays a central role in anti-viral responses. Following the detection of intracellular double-stranded DNA,…
Abstract Number: 2404 • ACR Convergence 2024
Nailfold Dermoscopy: A Valuable Tool for Differentiating Dermatomyositis from Systemic Lupus Erythematosus
Caroline Stone¹, Daniella Faden¹, Lillian Xie¹, Lais Lopes Almeida Gomes¹, Joshua Dan¹, Cristina Ricco¹, Ahmed Eldaboush¹ and Victoria Werth², ¹University of Pennsylvania, philadelphia, PA, ²University of Pennsylvania, Wynnewood, PA
Background/Purpose: Dermatoscopes are emerging as efficient, valuable alternatives to capillaroscopy for evaluating rheumatologic conditions. Second to systemic sclerosis, nailfold capillaroscopy abnormalities are most consistently reported…
Abstract Number: 0347 • ACR Convergence 2024
Dermato-polymyositis Mortality in U.S. Population: Declining Cancer and Cardiovascular Diseases Among the Leading Underlying Causes of Death over Two Decades
Elizabeth Matz¹ and Ram Singh², ¹UCLA David Geffen School of Medicine, Los Angeles, ²UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Dermatomyositis and polymyositis (DM/PM) are chronic inflammatory muscle diseases that may cause premature death due to progressive muscle weakness, lung disease, and disease and…
Abstract Number: 1158 • ACR Convergence 2024
Microvascular Differences Between Cancer and Non-cancer Anti-transcriptional Intermediary Factor 1 Gamma Antibody (anti-TIF1-γ) Associated Dermatomyositis Patients
Sehreen Mumtaz¹, Megan Sullivan², Maximiliano Diaz Menindez³, Emily Craver⁴ and Florentina Berianu⁵, ¹Mayo Clinic, Florida, Jacksonville, FL, ²Mayo Clinic Arizona, Scottsdale, AZ, ³Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵mayo clinic, Ponte Vedra Beach, FL
Background/Purpose: Nailfold videocapillaroscopy (NVC) findings have been studied to differ in different subsets of myositis-specific autoantibodies (MSAs) associated inflammatory myopathies. Prior investigations observed a statistically…
Abstract Number: 1731 • ACR Convergence 2024
Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Randomized, Treatment Delayed-Start Clinical Trial
hector Chinoy¹, Ashma Krishan¹, Yvonne Sylvestre¹, James Lilleker², Patrick Gordon³, Sarah Tansley⁴, Athiveeraramapandian Prabu⁵, Aamir Aslam⁶, Andrew Snedden⁷ and Janine Lamb⁸, ¹The University of Manchester, Manchester, United Kingdom, ²Northern Care Alliance NHS Trust, Salford, United Kingdom, ³nhs, London, United Kingdom, ⁴University of Bath, Bath, United Kingdom, ⁵Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, ⁶Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, ⁸University of Manchester, UK, Manchester, United Kingdom
Background/Purpose: The aim of the study was to assess the effects of baricitinib, a JAK1/2 inhibitor, following 24 weeks of active treatment on disease activity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].